MY139203A - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
MY139203A
MY139203A MYPI20022511A MYPI20022511A MY139203A MY 139203 A MY139203 A MY 139203A MY PI20022511 A MYPI20022511 A MY PI20022511A MY PI20022511 A MYPI20022511 A MY PI20022511A MY 139203 A MY139203 A MY 139203A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical composition
compositions
steroid
subcutaneous
diseases
Prior art date
Application number
MYPI20022511A
Other languages
English (en)
Inventor
Pierre Broqua
Martin Luck
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MY139203A publication Critical patent/MY139203A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MYPI20022511A 2001-07-12 2002-07-03 Pharmaceutical composition MY139203A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0117057.0A GB0117057D0 (en) 2001-07-12 2001-07-12 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
MY139203A true MY139203A (en) 2009-08-28

Family

ID=9918396

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20022511A MY139203A (en) 2001-07-12 2002-07-03 Pharmaceutical composition

Country Status (13)

Country Link
US (4) US20040038903A1 (cg-RX-API-DMAC7.html)
EP (1) EP1404357B1 (cg-RX-API-DMAC7.html)
JP (1) JP4845166B2 (cg-RX-API-DMAC7.html)
AR (1) AR036337A1 (cg-RX-API-DMAC7.html)
AT (1) ATE452648T1 (cg-RX-API-DMAC7.html)
DE (1) DE60234831D1 (cg-RX-API-DMAC7.html)
DK (1) DK1404357T3 (cg-RX-API-DMAC7.html)
ES (1) ES2338217T3 (cg-RX-API-DMAC7.html)
GB (1) GB0117057D0 (cg-RX-API-DMAC7.html)
MY (1) MY139203A (cg-RX-API-DMAC7.html)
PT (1) PT1404357E (cg-RX-API-DMAC7.html)
UY (1) UY27378A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003006049A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
ME00509B (me) 2002-09-27 2011-10-10 Zentaris Gmbh Oblik za terapijsku primjenu aktivnih peptida sa dugotrajnim oslobođenjem aktivnog sastojka i postupak za njihovo dobijanje
CA2540838C (en) 2003-10-03 2014-12-16 Thorn Bioscience, Llc Process for the synchronization of ovulation for timed breeding without heat detection
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
EP2120859B1 (en) * 2006-12-21 2013-11-20 Stryker Corporation Sustained-release formulations comprising bmp-7 crystals
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
ES2661240T3 (es) 2009-04-23 2018-03-28 Jbs United Animal Health Ii Llc Método y composición para sincronizar el momento de inseminación
JO3550B1 (ar) * 2009-05-01 2020-07-05 Ferring Int Center Sa مركب لمعالجة سرطان البروستاتا
KR101795643B1 (ko) * 2009-05-01 2017-11-09 훼링 비.브이. 전립선암 치료용 조성물
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
WO2012055903A1 (en) 2010-10-27 2012-05-03 Ferring B.V. Process for the manufacture of degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
KR102140982B1 (ko) 2012-06-01 2020-08-05 훼링 비.브이. 데가렐릭스의 제조 방법
ITMI20121638A1 (it) 2012-10-02 2014-04-03 Marco Sbracia Utilizzo di degarelix nel trattamento dell'endometriosi e di patologie ad essa correlate
WO2014085674A1 (en) 2012-11-28 2014-06-05 Jbs United Animal Health Ii Llc Method for synchronizing time of insemination in gilts
US10681261B2 (en) * 2012-11-30 2020-06-09 3I Avi, Llc Inspection system
TW201625218A (zh) * 2014-04-18 2016-07-16 Ｊｂｓ聯合動物保健有限責任公司 製造含ｇｎｒｈ凝膠之方法
JP6990717B2 (ja) * 2017-01-30 2022-02-03 アンテヴ リミテッド 少なくとも１種のｇｎｒｈアンタゴニストを含む組成物
WO2019110688A1 (en) 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
EP3560555A1 (en) 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US200486A (en) * 1878-02-19 Improvement in apparatus for attaching harness to the shafts
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ATE144538T1 (de) * 1991-04-25 1996-11-15 Romano Deghenghi Lhrh-antagonisten
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) * 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
TWI442932B (zh) * 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
ES2589322T3 (es) * 2008-02-11 2016-11-11 Safety Syringes, Inc. Jeringa con protector de seguridad de aguja y clip para evitar la liberación del protector durante un proceso de reconstitución
KR101795643B1 (ko) * 2009-05-01 2017-11-09 훼링 비.브이. 전립선암 치료용 조성물
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2012055903A1 (en) * 2010-10-27 2012-05-03 Ferring B.V. Process for the manufacture of degarelix and its intermediates
EP2447276A1 (en) * 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
EP2731607B1 (en) * 2011-07-15 2017-10-11 Ferring B.V. Method for timing a colonoscopy wherein a picosulate composition is administered

Also Published As

Publication number Publication date
US20040038903A1 (en) 2004-02-26
JP4845166B2 (ja) 2011-12-28
ES2338217T3 (es) 2010-05-05
AR036337A1 (es) 2004-09-01
GB0117057D0 (en) 2001-09-05
US20110053846A1 (en) 2011-03-03
US20090018085A1 (en) 2009-01-15
WO2003006049A1 (en) 2003-01-23
PT1404357E (pt) 2010-03-16
EP1404357B1 (en) 2009-12-23
ATE452648T1 (de) 2010-01-15
EP1404357A1 (en) 2004-04-07
JP2005511491A (ja) 2005-04-28
US20050245455A1 (en) 2005-11-03
UY27378A1 (es) 2003-02-28
DK1404357T3 (da) 2010-05-03
DE60234831D1 (de) 2010-02-04

Similar Documents

Publication Publication Date Title
UY27378A1 (es) Composición farmacéutica
EA200200778A1 (ru) СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С В ОРГАНИЗМЕ ХОЗЯИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ПРОТИВ ФЛАВИВИРУСА, СОЕДИНЕНИЕ ФОРМУЛЫ Ib - АКТИВНЫЙ АГЕНТ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С ИЛИ ФЛАВИВИРУСА (ВАРИАНТЫ)
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
MXPA05006572A (es) Composiciones y metodos para la administracion mejorada por via mucosa de peptidos fijadores al receptor de y2 y metodos para tratar y prevenir la obesidad.
MXPA05013340A (es) Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
CA2411754A1 (en) 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IT1252868B (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico
IL159087A0 (en) Bridged bicyclic compounds and pharmaceutical compositions containing the same
SE0100568D0 (sv) Compounds
ATE387430T1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
DK0975595T3 (da) Kokainanaloger
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
DE69810283D1 (de) GnRH ANTAGONISTEN
BRPI9708706C8 (pt) composição farmacêutica para administração intravenosa a um paciente
SE0100566D0 (sv) Compounds
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
SE0102440D0 (sv) New compound
AU7723700A (en) Non-mammalian gnrh analogs and uses thereof in regulation of fertility and pregnancy
MXPA02008870A (es) Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos.
BE2016C017I2 (cg-RX-API-DMAC7.html)